Aqueous Vascular Endothelial Growth Factor (VEGF) Levels in Type 3 Neovascularization

This study has been completed.
Sponsor:
Information provided by:
University of Molise
ClinicalTrials.gov Identifier:
NCT01350323
First received: May 2, 2011
Last updated: May 6, 2011
Last verified: March 2009

May 2, 2011
May 6, 2011
May 2009
September 2010   (final data collection date for primary outcome measure)
Aqueous VEGF concentration [ Time Frame: Change from baseline of VEGF concentration at month 1 ] [ Designated as safety issue: No ]
To establish if different types of wet-AMD were associated to different concentrations of VEGF at baseline
Same as current
Complete list of historical versions of study NCT01350323 on ClinicalTrials.gov Archive Site
Macular thickness assessment [ Time Frame: Change from baseline of macular thickness at month 1 ] [ Designated as safety issue: No ]
to compare central macular thickness before and after treatment respectively.
Same as current
Not Provided
Not Provided
 
Aqueous Vascular Endothelial Growth Factor (VEGF) Levels in Type 3 Neovascularization
Aqueous Humor Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Bevacizumab in Type 3 Versus Type 1 and 2 Neovascularization. A Prospective, Case-control Study.

This is a pilot, prospective, interventional, case-control study investigating aqueous levels of vascular endothelial growth factor (VEGF) in eyes with AMD-related neovascularization treated with intravitreal bevacizumab at the Medical Retina Department, University of Molise, Campobasso.

This was a pilot, prospective, interventional, case-control study investigating aqueous levels of VEGF in eyes with AMD-related NV treated with intravitreal bevacizumab.

Classification of neovascularization was based on its anatomic localization as ascertained by multimodal imaging employing FA (fluorescein angiography), ICGA (indocyanine green angiography) and OCT (optical coherence tomography) as recently proposed by Freund et al.

Diagnostic procedures and follow-up At baseline all the patients underwent BCVA measurement using early treatment diabetic retinopathy study (ETDRS) chart at 4 meters, fundus biomicroscopy, FA, ICGA and sd-OCT. All examinations were repeated in occasion of the follow-up appointments with exception of angiographic tests.

Angiographic tests and OCTs scans were recorded using Spectralis sd-OCT (Spectralis SD-OCT, Heidelberg Engineering, Heidelberg, Germany).

CMT was calculated after acquiring a sequence of 145 horizontal sections recorded in the high-resolution mode (1024 A-scans/30 degrees) and covering an area of 20 degrees (horizontal) × 15 degrees (vertical) with a distance of ~30 µm between individual sections. On follow-up examinations, the imaging processing software allowed reevaluation at exactly the same location.

The images were then processed by the "Thickness Map" analysis program. Field 1 of the map analysis protocol (central 1 mm) was used for central retinal thickness calculations.

Aqueous Sampling and Bevacizumab Injections All patients with AMD-related neovascularization received three intravitreal injections of 1.25 mg/0.05 ml of bevacizumab (Avastin; Genentech Inc, South San Francisco, California, USA) at baseline, month 1 and month 2.

Before injection, topical anesthesia was induced by tetracaine (1%) eye drops. Povidone-iodine was applied to the eyelid margins, the lashes, the conjunctiva bulbi and the fornices. After application of a sterile drape, a lid speculum was inserted.

Immediately before each intravitreal injection, aqueous sampling was performed by aspirating 0.05-0.1 ml of aqueous using a 30-gauge needle connected to a tuberculin syringe at the temporal limbus. All the samples were collected in the operating theatre under operating microscope control.

Intravitreal bevacizumab (IVB) injection was then performed using a 30-gauge needle in the inferotemporal quadrant at 3.5 mm to 4 mm posterior to the limbus.

The undiluted aqueous samples were transferred into sterile containers and immediately stored in a -80°C freezer until analysis.

Control Group Reference samples were obtained from 14 age-matched patients undergoing cataract surgery.

Aqueous humor samples were obtained in the same fashion described above for eyes with wet-AMD. The undiluted aqueous samples were transferred into sterile containers and immediately stored in a -80°C freezer until analysis.

Vascular Endothelial Growth Factor Assay Collected samples were gradually equilibrated to room temperature before beginning the assay and diluted 1:1 with the sample diluent provided by the manufacturer.

The VEGF content was determined on 50 µl of diluted sample with a human VEGF ELISA kit (EHVEGF, Pierce Biotechnology, Rockford, Illinois, USA) according to the manufacturer's instruction and using an extended standard curve including a 16, 8 and 4 pg/ml standard point. All assays were performed in duplicate. The minimum detectable concentration of VEGF was 3.5 pg/ml. Values inferior to 3.5pg/ml were considered equal to 1 for statistical analysis.

Interventional
Not Provided
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Age-related Macular Degeneration
  • Procedure: Aqueous sample
    Aqueous sample (0.1ml of aqueous)+ intravitreal injection of bevacizumab (1.25mg/0.05ml)
    Other Name: Avastin
  • Procedure: Aqueous sample
    Aqueous sample (0.1ml)+intravitreal injection of bevacizumab (1.25mg/0.05ml)
    Other Name: Avastin
  • Procedure: Aqueous sample
    Aqueous sample (0.1ml)+ intravitreal injection of bevacizumab (1.25mg/0.05ml)
    Other Name: Avastin
  • Procedure: Aqueous sample
    Aqueous sample (0.1ml)
    Other Name: Avastin
  • Active Comparator: Type 3 NV
    Wet-AMD related type 3 neovascularization
    Intervention: Procedure: Aqueous sample
  • Active Comparator: Type 2 NV
    Wet-AMD related type 2 neovascularization
    Intervention: Procedure: Aqueous sample
  • Active Comparator: Type 1 NV
    Wet-AMD related type 1 neovascularization
    Intervention: Procedure: Aqueous sample
  • Controls
    Aqueous sample (0.1ml) in patients undergoing cataract extraction
    Intervention: Procedure: Aqueous sample

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
33
September 2010
September 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • wet age-related macular degeneration type 1, 2 or 3

Exclusion Criteria:

  • BCVA at baseline less than 1.0 logMAR
  • any previous treatment of the neovascular lesion
  • previous vitrectomy
  • laser coagulation within the last 3 months
  • previous participation in any studies using investigational drugs within 3months preceding day 0
  • intraocular surgery (including cataract surgery) in the study eye within 3 months preceding day 0
  • glaucoma in the study eye; diabetes mellitus
  • use of immunosuppressive drugs
  • malignant tumors of any location
Both
55 Years to 95 Years
No
Contact information is only displayed when the study is recruiting subjects
Italy
 
NCT01350323
UM-O-1
No
Roberto dell'Omo, University of Molise
University of Molise
Not Provided
Principal Investigator: Roberto dell'Omo, MD University of Molise
Study Director: Ciro Costagliola, Professor University of Molise
University of Molise
March 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP